Adriana Rossi

8PUBLICATIONS
95CO-AUTHORS
Haematological tumoursGene and molecular therapyRegenerative medicine (incl. stem cells)Cancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 13, 2025
Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.

Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar

|Aug 08, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Jul 09, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Jun 26, 2025
Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma.

Jack Khouri, Douglas Sborov, Adriana Rossi

|Jun 03, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

Sundar Jagannath, Thomas G Martin, Yi Lin

|Feb 26, 2025
Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis.

Bruno Almeida Costa, Danai Dima, Tomer Mark

Pageof 2

Frequent Collaborators

5 joint publications

Shambavi Richard

4 joint publications

Sundar Jagannath

4 joint publications

Samir S Parekh

4 joint publications

Alex Lieberman-Cribbin